Oxford, 22 November, 2016
Oxford MEStar Ltd (“MEStar”), an Oxford University spin-out, today announced that the company has entered into a non-binding letter of intent (LOI) with Elanix Biotechnologies AG. The LOI contains broad terms of a potential transaction whereby the two companies, together with Tianjin-based UniNova, might establish a Chinese JV. In the first instance this would market Elanix’s GynRepair, used for the treatment of vulvodynia, in the domestic market in China (PRC). The transaction is necessarily subject to entering into a definitive agreement between the parties, containing specific signing and closing terms and conditions yet to be finalised, negotiated and agreed up.
Professor Zhanfeng Cui, the founder of MEStar, commented: “We look forward to collaborating with Elanix, whose tissue repair products we believe have significant commercial potential”.
Tomas Svoboda, CEO of Elanix Biotechnologies AG, added: “We are very pleased to find such reputable partners that will accelerate our territorial expansion for our innovative bioactive creams”.
Oxford MEStar Limited is a spin-out company from the Institute of Biomedical Engineering of Oxford University
specializing in translational and regenerative medicine and healthcare. The company is focused on a) developing novel technologies; b) offering bioengineering solutions to clients; and c) technology transfer between Europe and China.
For more information, please contact Dr Zoe Li on 01865 784436 or visit www.oxford-mestar.com
 | UniNova is the Oxford MESTAR sister company, incorporated in Nov 2014 with 80 million RMB private investment and with the support of Tianjin Municipal Government. UniNova’s goal is to provide a one-stop solution for SMEs in biotechnology, biomedical and healthcare, so they can land in China smoothly and access the Chinese market in a timely manner. |
Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynaecological applications, and provides services in cell technologies. The company was founded in 2013 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks with vast quantities of cells of different cell types.
The Company is headquartered in Nyon, Switzerland with offices in Potsdam and listed on the Frankfurt stock exchange under the symbol ELN. For more information and updates, visit www.elanix-biotechnologies.com.
Maria Widowski, Elanix Biotechnologies AG
investor.relations@elanix.ch | Phone number: +49 331 583 945 10
Serena de Nahlik, Oxford MEStar Limited
serena.denahlik@oxford-mestar.com | Phone number: +44 1865 784435
